Drug intelligence / Profile preview

Foot and Mouth Disease Vaccine (US Biologic)

Development stage: Preclinical
Lead developer: US Biologic
Modality: Vaccines & Immunotherapeutics
Administration: Oral

Overview

US Biologic is developing an oral vaccine for Foot and Mouth Disease (FMD) utilizing its proprietary OrisBio platform. This technology employs *Bacillus subtilis* (*B. subtilis*) spores as a delivery vehicle to express Foot-and-Mouth Disease Virus (FMDV) antigens. The vaccine is designed for oral administration to livestock, where the spores facilitate the delivery of antigens to the mucosal immune system to elicit protective immunity. The program is currently in the preclinical stage and is being developed in collaboration with the Department of Homeland Security (DHS) Plum Island Animal Disease Center.

Other names: FMDV oral vaccineOrisBio FMDV vaccineFoot-and-Mouth Disease Vaccine

Beyond the preview

Go deeper on Foot and Mouth Disease Vaccine (US Biologic).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Foot and Mouth Disease Vaccine (US Biologic).

Explore the full profile